{"id":"W2793901188","doi":"10.1200/jco.2018.36.6_suppl.686","title":"Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) <i>v</i> sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Discontinuation; Adverse effect; Sunitinib; Renal cell carcinoma; Clinical endpoint; Nivolumab; Toxicity; Gastroenterology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001604212,0.0002409882,0.0006424782,0.0002571067,0.0001075642,0.000398713,0.0002950353,0.0004114923,0.001800189],"category_scores_gemma":[0.001379274,0.0001556608,0.0009547736,0.0001834022,0.000250856,0.0003997642,0.0002094423,0.0006075447,0.0002033971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005441974,"about_ca_system_score_gemma":0.0003411075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003041151,"about_ca_topic_score_gemma":0.0008777108,"domain_scores_codex":[0.9995072,0.0002376136,0.00004025569,0.00008007525,0.0000908764,0.00004391818],"domain_scores_gemma":[0.9991714,0.000312148,0.0003083628,0.00005065128,0.00003101265,0.0001264708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5127222,0.007922168,0.1533304,0.001091392,0.00342789,0.0001786362,0.0002184373,0.007153971,0.07245984,0.0004093763,0.001932519,0.2391531],"study_design_scores_gemma":[0.04686709,0.4193486,0.4893916,0.0001229674,0.005594904,0.001217873,0.0001094306,0.009801619,0.01941975,0.0009161795,0.007128684,0.0000812514],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964886,0.001826239,0.0003847207,0.00009819182,0.00001267217,0.0001772253,0.0002875191,0.00001242158,0.0007123996],"genre_scores_gemma":[0.9988276,0.0002299735,0.0003010889,0.00008940795,0.00001701913,0.00007547459,0.0002824235,0.000003689444,0.0001732334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001800189,"threshold_uncertainty_score":0.008484006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07046305125117139,"score_gpt":0.3823335965970854,"score_spread":0.3118705453459141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}